Longeveron Inc.

Longeveron Inc. is a U.S.-based clinical-stage biotechnology company developing laromestrocel, a cell therapy platform focused on regenerative medicine and inflammatory/degenerative diseases. It also generates limited revenue from Bahamas Registry Trials and contract development/manufacturing services while it advances FDA-enabling work for its lead programs.

−1 875,5 %

67,0 %

−1 893,6 %

−49,9 %

1.33

1.33

— Longeveron Inc.
%
Cell therapy clinical programs55% Development of laromestrocel and related clinical/regulatory activities for lead indications.
Bahamas Registry Trials25% Fee-based investigational treatment administration and trial participation in The Bahamas.
Contract development and manufacturing services15% Fee-for-service research, process development, manufacturing, and testing work for third parties.
Grant revenue5% Non-dilutive research funding from NIH, Alzheimer’s Association, and Maryland Stem Cell Research Fund.

Longeveron’s direct customers are a mix of clinical trial participants, third-party biotechnology clients, and...

  • Bahamas Registry Trial participantsprimary

    Patients pay to participate in the registry trial and receive laromestrocel administration in Nassau.

  • Third-party biotechnology customerssecondary

    Buy contract development, manufacturing, stability testing, and reserved suite capacity.

  • Grant-making institutionssecondary

    Provide non-dilutive funding for clinical research programs and performance-based milestones.

  • Clinical trial and regulatory stakeholdersprimary

    Support the company’s FDA pathway through trials, CMC work, and BLA-enabling activities.

Longeveron is headquartered in the United States and conducts most of its corporate, research, and regulatory activity...

  • •United States is the main base for R&D, regulatory, and corporate activity
  • •The Bahamas is important for Registry Trial revenue and patient administration
  • •Nassau clinics are the operational site for laromestrocel administration
  • •U.S. FDA pathway drives most development spending and execution risk
  • •Geographic concentration makes trial access and local approvals important

The company is prioritizing FDA-enabling work for its lead programs, especially CMC readiness and manufacturing...

01
FDA/BLA-enabling executionshort-term

Regulatory progress is the main value driver and determines whether laromestrocel can reach commercialization.

02
Financing and runway extensionshort-term

The company needs additional capital to fund operations and development through key milestones.

03
Partnerships for pipeline programsmedium-term

Partnering can reduce funding burden and improve development optionality for larger indications.

Longeveron faces high execution risk because its lead product is still investigational and depends on successful...

critical

Clinical and regulatory failure

Lead programs are investigational and must clear complex FDA review and BLA-enabling requirements.

Scope
HLHS and Alzheimer’s programs
Materiality
high
critical

Liquidity and going-concern pressure

The company has recurring losses, limited cash runway, and needs additional funding to continue operations.

Scope
Corporate operations and development programs
Materiality
high
high

Nasdaq delisting risk

The stock has fallen below the minimum bid price requirement, which can reduce liquidity and investor access.

Scope
Class A common stock
Materiality
medium
high

Revenue concentration and volatility

Revenue depends on a small number of sources, including registry trials and one manufacturing customer relationship.

Scope
Bahamas Registry Trials and contract manufacturing
Materiality
medium
Revenue recognition for contract manufacturing
Can shift revenue between quarters and affect gross margin
Grant revenue recognition
Creates timing differences versus funding receipts
Going-concern and liquidity assumptions
Affects disclosure and investor assessment of survival risk
Equity-based compensation
Raises operating expenses without cash outflow

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

Dogwood Therapeutics, Inc.

DWTX · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

Longevity Health Holdings, Inc.

XAGE · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics

LadRx Corp

Biological Products, (No Diagnostic Substances)

Enliven Therapeutics, Inc.

ELVN · Pharmaceutical Preparations

: 28/04/2026